Privium Fund Management B.V. Decreases Stake in ProQR Therapeutics (NASDAQ:PRQR)

Privium Fund Management B.V. reduced its position in ProQR Therapeutics (NASDAQ:PRQR) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,985,633 shares of the biopharmaceutical company’s stock after selling 646,755 shares during the quarter. ProQR Therapeutics comprises about 3.0% of Privium Fund Management B.V.’s holdings, making the stock its 7th biggest holding. Privium Fund Management B.V. owned 6.10% of ProQR Therapeutics worth $13,212,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Platinum Investment Management Ltd. purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $4,076,000. M&T Bank Corp purchased a new stake in shares of ProQR Therapeutics in the fourth quarter worth $330,000. Raymond James Financial Inc. bought a new stake in ProQR Therapeutics during the fourth quarter valued at $260,000. BNP Paribas Financial Markets boosted its stake in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares during the period. Finally, OneDigital Investment Advisors LLC grew its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

Wall Street Analysts Forecast Growth

PRQR has been the topic of several recent analyst reports. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, March 14th. JMP Securities reissued a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, HC Wainwright lifted their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $9.50.

ProQR Therapeutics Stock Performance

PRQR stock opened at $1.64 on Wednesday. The company has a market capitalization of $133.96 million, a PE ratio of -5.13 and a beta of 0.24. ProQR Therapeutics has a one year low of $1.61 and a one year high of $4.62. The company’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $2.62.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).